The AGEhiV cohort study has expanded their study to investigate what the effect of the COVID-19 virus is on their included participants. The original focus of this cohort is to examine the effects of aging and additional comorbidities on people with and without HIV. One of the aims of the expansion of the data is to observe what COVID-19 does with antibody seroconversion and antibody titres in HIV-positive AGEhiV participants, and if there is a difference with HIV-negative participants. Moreover, they want to retrospectively compare the incidence of people who have developed COVID-19 and the disease severity of HIV-positive and –negative participants. A third and last aim of the expansion of the study is to assess factors associated with COVID-19 seroconversion, the development of COVID-19 and progressing to severe disease in both HIV-positive and negative participants. Factors to be taken into account amongst others will include demographic characteristics, presence of pre-existing co-morbidities, use of particular antiretrovirals against HIV, and immunological parameters.
If you have any questions regarding the research, please contact Peter Reiss
APH researchers involved in this study: Peter Reiss together with Marc van der Valk, Maarten Schim van der Loeff, Neeltje Kootstra and Maria Prins
This is an initiative taken by APH researchers as a result of the COVID-19 outbreak. If you have an initiative to be listed as well, please email us.
Back to main page APH COVID-19 initiatives